Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Similar articles for PubMed (Select 15802410)

1.

Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial.

Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V, Kulakov V.

Obstet Gynecol. 2005 Apr;105(4):811-5.

PMID:
15802410
2.

Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.

Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Järvelin MR, Pouta A.

Am J Obstet Gynecol. 2008 Nov;199(5):529.e1-529.e10. doi: 10.1016/j.ajog.2008.04.013. Epub 2008 Jun 4.

PMID:
18533124
3.

Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A.

Godfrey EM, Memmel LM, Neustadt A, Shah M, Nicosia A, Moorthie M, Gilliam M.

Contraception. 2010 Feb;81(2):123-7. doi: 10.1016/j.contraception.2009.09.004. Epub 2009 Oct 8.

PMID:
20103449
4.

Contraception in perimenopausal women with diabetes mellitus.

Grigoryan OR, Grodnitskaya EE, Andreeva EN, Shestakova MV, Melnichenko GA, Dedov II.

Gynecol Endocrinol. 2006 Apr;22(4):198-206.

PMID:
16723306
5.

Intrauterine devices: an effective alternative to oral hormonal contraception.

[No authors listed]

Prescrire Int. 2009 Jun;18(101):125-30.

PMID:
19637436
7.

Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study.

Kayikcioglu F, Gunes M, Ozdegirmenci O, Haberal A.

Contraception. 2006 May;73(5):528-31. Epub 2006 Mar 23.

PMID:
16627040
8.

Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study.

Ng YW, Liang S, Singh K.

Contraception. 2009 Jan;79(1):24-8. doi: 10.1016/j.contraception.2008.07.012. Epub 2008 Sep 18.

PMID:
19041437
10.

Use of the NuvaRing hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus.

Grigoryan OR, Grodnitskaya EE, Andreeva EN, Chebotnikova TV, Melnichenko GA.

Gynecol Endocrinol. 2008 Feb;24(2):99-104. doi: 10.1080/09513590701708795.

PMID:
18210334
11.

[Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].

Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A.

Rev Assoc Med Bras. 2006 Jan-Feb;52(1):32-6. Epub 2006 Apr 10. Portuguese.

12.

Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.

Lehtovirta P, Paavonen J, Heikinheimo O.

Contraception. 2007 Jan;75(1):37-9. Epub 2006 Oct 25.

PMID:
17161122
13.

The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).

van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM.

Thromb Haemost. 2009 Apr;101(4):691-5.

PMID:
19350113
15.

Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.

Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R.

Menopause. 2008 Sep-Oct;15(5):1002-4. doi: 10.1097/gme.0b013e3181659837.

PMID:
18451744
17.

Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia.

Kriplani A, Singh BM, Lal S, Agarwal N.

Int J Gynaecol Obstet. 2007 Jun;97(3):190-4. Epub 2007 Mar 26.

PMID:
17382331
18.

Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.

Kesim MD, Aydin Y, Atis A, Mandiraci G.

Climacteric. 2008 Jun;11(3):252-7. doi: 10.1080/13697130802163168.

PMID:
18568790
19.

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.

Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L.

Contraception. 2009 Jul;80(1):84-9. doi: 10.1016/j.contraception.2009.01.004. Epub 2009 Feb 27.

PMID:
19501221
20.

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.

PMID:
16199244
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk